JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institut d'Investigacions Biomèdiques August Pi i Sunyer (22)
2023
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
2022
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
2021
2020
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
2019
-
Insights on Multiple Myeloma Treatment Strategies
HemaSphere, Vol. 3, Núm. 1
2016
-
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
Blood, Vol. 127, Núm. 4, pp. 420-425
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
-
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
Leukemia, Vol. 29, Núm. 5, pp. 1186-1194
2014
-
European perspective on multiple myeloma treatment strategies in 2014
Oncologist, Vol. 19, Núm. 8, pp. 829-844
-
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial
The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206
2013
-
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study
British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234
-
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach
Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74
-
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients
British Journal of Haematology, Vol. 162, Núm. 4, pp. 474-482
2012
-
SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status
Leukemia, Vol. 26, Núm. 12, pp. 2521-2529
2010
2009
-
Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma
CLINICAL LYMPHOMA & MYELOMA
-
The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network
Annals of Oncology, Vol. 20, Núm. 8, pp. 1303-1317
2008
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression
Haematologica, Vol. 93, Núm. 4, pp. 560-565